Europe’s life sciences industry has a long and successful history of bringing cutting-edge therapies to the market. But the region risks falling behind the rest of the world without increased investment in innovation. Policymakers and industry leaders face some critical decisions as the European Commission debates the first major legislative overhaul of the industry in more than 20 years. The flow of capital to other parts of the world is also something for European leaders to address.
Stefan Oelrich, Member of the Board of Management and President of Pharmaceuticals, Bayer AG, shared his insights on how to strengthen Europe’s pharmaceutical industry during this video interview with Oliver Wyman’s Rolf Fricker and Andreas Eggert. It was recorded during the Oliver Wyman Health and Life Sciences Innovation Forum.